AnaptysBio Inc
NASDAQ:ANAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AnaptysBio Inc
NASDAQ:ANAB
|
US |
|
Consolidated Edison Inc
NYSE:ED
|
US |
|
Babcock & Wilcox Enterprises Inc
NYSE:BW
|
US |
|
Tetra Tech Inc
NASDAQ:TTEK
|
US |
|
Margaret Lake Diamonds Inc
OTC:KNXFF
|
CA |
|
Novo Nordisk A/S
NYSE:NVO
|
DK |
|
Paychex Inc
NASDAQ:PAYX
|
US |
|
ARC Resources Ltd
TSX:ARX
|
CA |
|
Gecina SA
OTC:GECFF
|
FR |
|
S
|
Somboon Advance Technology PCL
SET:SAT
|
TH |
|
AirIQ Inc
XTSX:IQ
|
CA |
|
I
|
Intrum AB
F:IJU
|
SE |
|
Rentokil Initial PLC
LSE:RTO
|
UK |
|
C
|
Compagnie d'entreprises CFE SA
XBRU:CFEB
|
BE |
|
BioNTech SE
NASDAQ:BNTX
|
DE |
|
B
|
Beneficient
NASDAQ:BENF
|
US |
Wall St Price Targets
ANAB Price Targets Summary
AnaptysBio Inc
According to Wall Street analysts, the average 1-year price target for ANAB is 84.25 USD with a low forecast of 60.6 USD and a high forecast of 147 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ANAB's stock price target?
Price Target
84.25
USD
According to Wall Street analysts, the average 1-year price target for ANAB is 84.25 USD with a low forecast of 60.6 USD and a high forecast of 147 USD.
What is the Revenue forecast for AnaptysBio Inc?
Projected CAGR
22%
Over the last 11 years, the compound annual growth rate for Revenue has been 28%. The projected CAGR for the next 8 years is 22%.
What is the Operating Income forecast for AnaptysBio Inc?
Projected CAGR
36%
Over the last 11 years, the compound annual growth rate for Operating Income has been 23%. The projected CAGR for the next 8 years is 36%.
